These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12877306)

  • 1. Osteoporosis associated with the treatment of paraphilias: a clinical review of seven case reports.
    Grasswick LJ; Bradford JM
    J Forensic Sci; 2003 Jul; 48(4):849-55. PubMed ID: 12877306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series.
    Saleh FM; Niel T; Fishman MJ
    J Forensic Sci; 2004 Nov; 49(6):1343-8. PubMed ID: 15568711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hypersexual paraphilic patient treated with leuprolide acetate: a single case report.
    Saleh F
    J Sex Marital Ther; 2005; 31(5):433-44. PubMed ID: 16169826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment of paraphilic and nonparaphilic sexual disorders.
    Guay DR
    Clin Ther; 2009 Jan; 31(1):1-31. PubMed ID: 19243704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Male osteoporosis associated with longterm cyproterone treatment.
    Vasireddy S; Swinson DR
    J Rheumatol; 2001 Jul; 28(7):1702-3. PubMed ID: 11469484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
    Spry NA; Galvão DA; Davies R; La Bianca S; Joseph D; Davidson A; Prince R
    BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
    Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihormonal treatment of paraphilic patients in German forensic psychiatric clinics.
    Czerny JP; Briken P; Berner W
    Eur Psychiatry; 2002 Apr; 17(2):104-6. PubMed ID: 11973119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depot-leuprolide acetate for treatment of paraphilias: a report of twelve cases.
    Krueger RB; Kaplan MS
    Arch Sex Behav; 2001 Aug; 30(4):409-22. PubMed ID: 11446201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
    Malone S; Perry G; Segal R; Dahrouge S; Crook J
    BJU Int; 2005 Sep; 96(4):514-20. PubMed ID: 16104902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of sex offenders with leuprorelin].
    Nøttestad JA; Bjarnar E; Lundmo PI; Sandvik M
    Tidsskr Nor Laegeforen; 2006 Feb; 126(5):633-4. PubMed ID: 16505878
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM; Pasini J; Mareković Z
    Coll Antropol; 2005 Dec; 29(2):589-91. PubMed ID: 16417166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review.
    Briken P; Hill A; Berner W
    J Clin Psychiatry; 2003 Aug; 64(8):890-7. PubMed ID: 12927003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex hormones, neurotransmitters, and psychopharmacological treatments in men with paraphilic disorders.
    Saleh FM; Berlin FS
    J Child Sex Abus; 2003; 12(3-4):233-53. PubMed ID: 15308453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
    Green HJ; Pakenham KI; Headley BC; Yaxley J; Nicol DL; Mactaggart PN; Swanson CE; Watson RB; Gardiner RA
    BJU Int; 2004 May; 93(7):975-9. PubMed ID: 15142146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term side-effects following cyproterone acetate containing therapy in gynecology].
    Regidor PA; Speer K; Regidor M; Schindler EM
    Zentralbl Gynakol; 2000; 122(5):268-73. PubMed ID: 10857213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.